Document is current
Any future updates will be listed below
-
Authors
Skuli, Sarah J. https://orcid.org/0000-0001-7711-0732
Bakayoko, A’ishah
Kruidenier, Marisa
Manning, Bryan
Pammer, Paige
Salimov, Akmal https://orcid.org/0009-0002-0186-3708
Riley, Owen
Brake-Sillá, Gisela
Dopkin, Derrick
Bowman, Michael
Martinez-Gutierrez, Leslie N.
Anderson, Colin C.
Reisz, Julie A.
Buono, Roberta https://orcid.org/0000-0002-0033-5375
Paul, Madhuri
Saland, Estelle
Liccardo, Francesca https://orcid.org/0000-0002-6391-9925
DeVine, Ann
Wong, Sarah
Xu, Jimmy P.
Nee, Eva https://orcid.org/0000-0002-7838-6586
Hausler, Ryan
Boettcher, Steffen
Sebti, Said M.
Lai, Catherine
Maxwell, Kara N. https://orcid.org/0000-0001-8192-4202
Sarry, Jean-Emmanuel https://orcid.org/0000-0002-6704-2032
Fruman, David A. https://orcid.org/0000-0002-1796-5162
D’Alessandro, Angelo https://orcid.org/0000-0002-2258-6490
Mesaros, Clementina
Keith, Brian
Simon, M. Celeste
Sung, Pamela J. https://orcid.org/0000-0002-5828-5622
Wertheim, Gerald
Skuli, Nicolas
Bowman, Robert L. https://orcid.org/0000-0002-8294-8748
Matthews, Andrew
Carroll, Martin https://orcid.org/0000-0002-5622-3735
- License Information
-
More Information
Article History
Received: 5 December 2024
Revised: 20 May 2025
Accepted: 13 June 2025
First Online: 9 July 2025
Competing interests
: SMS is co-inventor of GGTI-2418/17 and is Scientific Founder of Prescient Therapeutics, the company that licensed GGTI-2418/17 and sponsoring current clinical trials. Competing interests for unrelated studies include the following: CL is a consultant for Bristol Myers Squibb (BMS), AbbVie and Astellas; CL is on advisory boards for Servier, Daiichi, AbbVie, Rigel and Genentech; CL receives research funding from JAZZ and BMS; DAF is a consultant for AbbVie. Other authors declare no relevant competing interests.
: All methods were performed in accordance with the relevant guidelines and regulations. All animal-related experiments received ethical approval from the UPenn Institutional Animal Care and Use Committee (IACUC Protocol #803506). The use of deidentified human samples and data collected from the electronic health record received ethical approval from the UPenn and Roswell Park Comprehensive Cancer Center Institutional Review Boards (IRB Protocols #703185 and #BDR173423, respectively). Informed consent was obtained from all participants.
